These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 16503874)

  • 1. Matrix metalloproteinases: a potential therapeutic target in atherosclerosis.
    Rouis M
    Curr Drug Targets Cardiovasc Haematol Disord; 2005 Dec; 5(6):541-8. PubMed ID: 16503874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene expression levels of matrix metalloproteinases in human atherosclerotic plaques and evaluation of radiolabeled inhibitors as imaging agents for plaque vulnerability.
    Müller A; Krämer SD; Meletta R; Beck K; Selivanova SV; Rancic Z; Kaufmann PA; Vos B; Meding J; Stellfeld T; Heinrich TK; Bauser M; Hütter J; Dinkelborg LM; Schibli R; Ametamey SM
    Nucl Med Biol; 2014 Aug; 41(7):562-9. PubMed ID: 24853402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vulnerable atherosclerotic plaque metalloproteinases and foam cell phenotypes.
    Newby AC; George SJ; Ismail Y; Johnson JL; Sala-Newby GB; Thomas AC
    Thromb Haemost; 2009 Jun; 101(6):1006-11. PubMed ID: 19492140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Matrix metalloproteinases: influence on smooth muscle cells and atherosclerotic plaque stability.
    Johnson JL
    Expert Rev Cardiovasc Ther; 2007 Mar; 5(2):265-82. PubMed ID: 17338671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Matrix metalloproteinases and atherosclerosis.
    Watanabe N; Ikeda U
    Curr Atheroscler Rep; 2004 Mar; 6(2):112-20. PubMed ID: 15023295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic potential of matrix metalloproteinase inhibitors in atherosclerosis.
    George SJ
    Expert Opin Investig Drugs; 2000 May; 9(5):993-1007. PubMed ID: 11060722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence for the Involvement of Matrix-Degrading Metalloproteinases (MMPs) in Atherosclerosis.
    Brown BA; Williams H; George SJ
    Prog Mol Biol Transl Sci; 2017; 147():197-237. PubMed ID: 28413029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Macrophage-mediated proteolytic remodeling of the extracellular matrix in atherosclerosis results in neoepitopes: a potential new class of biochemical markers.
    Skjøt-Arkil H; Barascuk N; Register T; Karsdal MA
    Assay Drug Dev Technol; 2010 Oct; 8(5):542-52. PubMed ID: 20662734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multidimensional Contribution of Matrix Metalloproteinases to Atherosclerotic Plaque Vulnerability: Multiple Mechanisms of Inhibition to Promote Stability.
    Ruddy JM; Ikonomidis JS; Jones JA
    J Vasc Res; 2016; 53(1-2):1-16. PubMed ID: 27327039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Do metalloproteinases destabilize vulnerable atherosclerotic plaques?
    Newby AC
    Curr Opin Lipidol; 2006 Oct; 17(5):556-61. PubMed ID: 16960505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture.
    Shah PK; Falk E; Badimon JJ; Fernandez-Ortiz A; Mailhac A; Villareal-Levy G; Fallon JT; Regnstrom J; Fuster V
    Circulation; 1995 Sep; 92(6):1565-9. PubMed ID: 7664441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Raloxifene inhibits matrix metalloproteinases expression and activity in macrophages and smooth muscle cells.
    Bellosta S; Baetta R; Canavesi M; Comparato C; Granata A; Monetti M; Cairoli F; Eberini I; Puglisi L; Corsini A
    Pharmacol Res; 2007 Aug; 56(2):160-7. PubMed ID: 17582780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of matrix metalloproteinases on atherosclerosis.
    Lin J; Kakkar V; Lu X
    Curr Drug Targets; 2014 Apr; 15(4):442-53. PubMed ID: 24517161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition on serum matrix metalloproteinase-13 and tissue inhibitor matrix metalloproteinase-1 levels as a sign of plaque stabilization.
    Cevik C; Otahbachi M; Nugent K; Warangkana C; Meyerrose G
    J Cardiovasc Med (Hagerstown); 2008 Dec; 9(12):1274-8. PubMed ID: 19001938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Matrix metalloproteinases, inflammation and atherosclerosis: therapeutic perspectives.
    Beaudeux JL; Giral P; Bruckert E; Foglietti MJ; Chapman MJ
    Clin Chem Lab Med; 2004 Feb; 42(2):121-31. PubMed ID: 15061349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibiting extracellular matrix metalloproteinase inducer maybe beneficial for diminishing the atherosclerotic plaque instability.
    Xie S; Nie R; Wang J
    J Postgrad Med; 2009; 55(4):284-6. PubMed ID: 20083879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Matrix metalloproteinase inhibition with tetracyclines for the treatment of coronary artery disease.
    Bench TJ; Jeremias A; Brown DL
    Pharmacol Res; 2011 Dec; 64(6):561-6. PubMed ID: 21624471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Matrix metalloproteinases and atherogenesis in dependence of age.
    Kunz J
    Gerontology; 2007; 53(2):63-73. PubMed ID: 17047333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Metalloproteinases: therapeutic target in atherosclerosis].
    Jguirim-Souissi I; Jelassi A; Najah M; Rouis M; Slimane MN
    Tunis Med; 2008 May; 86(5):490-6. PubMed ID: 19469306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteinases and plaque rupture: unblocking the road to translation.
    Newby AC
    Curr Opin Lipidol; 2014 Oct; 25(5):358-66. PubMed ID: 25089553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.